SAB Biotherapeutics Inc
SAB Biotherapeutics Inc (SABS) Options Open Interest
SABS options open interest is — contracts. The 2-week average daily volume is 213 contracts across the chain.
Read more
Monitoring SABS open interest helps you see where real money is positioned on SAB Biotherapeutics Inc's options and which strikes are attracting the most commitment from traders. SAB Biotherapeutics Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor SABS options open interest in real time and find the strikes that matter.
Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising SABS options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect SAB Biotherapeutics Inc to settle.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors.
Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.
Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where SABS open interest is concentrated. Our scanner maps SAB Biotherapeutics Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade SAB Biotherapeutics Inc's options open interest as the signal it is, not as an afterthought.
| 3.00 | 0.05 | 0.85 | 0.45 | 191% | +0.6054 | 2,258 |
| 4.00 | — | 0.30 | 0.30 | 273% | +0.3787 | 640 |
| 8.00 | — | 0.25 | 0.25 | 486% | +0.2359 | 359 |
| 5.00 | — | 2.15 | 2.15 | 1,000% | +0.7186 | 233 |
| 6.00 | — | 2.10 | 2.10 | 1,000% | +0.6817 | 7 |
| 3.00 | — | 0.25 | 0.25 | 144% | -0.3970 | 137 |
| 4.00 | — | 2.90 | 2.90 | 1,000% | -0.2392 | 20 |
| 1.00 | — | 0.75 | 0.75 | 1,000% | -0.0645 | 18 |
| 6.00 | 1.00 | 4.90 | 2.95 | 259% | -0.8967 | 6 |
| 2.00 | — | 2.15 | 2.15 | 1,000% | -0.1328 | 1 |
As of October 5, 2026
Follow the money
Track SABS open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.
Start your 14-day free trial→